clinical trial · NCT07442630
Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides
JW Pharmaceutical·phase4·active not recruiting·n = 88
HypercholesterolemiaPitavastatin 4mgEzetimibe 10 mgPlacebo (for Pitavastatin/Ezetimibe)Placebo (for Pitavastatin)
brief summary
A multicenter, randomized, double-blind, phase Ⅳ study to evaluate the long-term efficacy and safety of Pitavastatin/Ezetimibe and Pitavastatin in patients with hypercholesterolemia with elevated triglycerides
started
Aug 21, 2023
primary completion
Jan 22, 2026
completion
Nov 30, 2026
last updated
Mar 2, 2026
detailed description
A multicenter study to evaluate efficacy and safety
official title
A Multicenter Study to Evaluate Efficacy and Safety
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol